Tesamorelin 10 mg

Descrizione

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence with structural modifications that improve stability and resistance to enzymatic degradation.

Unlike GHRP peptides, which stimulate the ghrelin receptor (GHSR-1a), Tesamorelin acts directly on the GHRH receptor in the anterior pituitary, promoting physiological pulsatile secretion of endogenous growth hormone. This receptor selectivity has made Tesamorelin one of the most thoroughly investigated peptides in growth hormone physiology and metabolic research.

Why Tesamorelin matters in endocrine research

Tesamorelin differs from many secretagogues because it closely mimics the body’s natural GHRH signalling rather than activating ghrelin pathways.

Published research has investigated Tesamorelin in relation to:

• pulsatile growth hormone secretion
• Regolazione dell'IGF-1
• body composition
• visceral adipose tissue
• hepatic fat
• fisiologia endocrina
• metabolic regulation
• funzione ipofisaria

Its extensive human evidence base has established Tesamorelin as one of the best-characterised GHRH analogues available for metabolic and endocrine research.

How Tesamorelin works

Unlike GHRP peptides, Tesamorelin activates the growth hormone-releasing hormone receptor (GHRHR).

La ricerca pubblicata ha esplorato la sua relazione con:

Growth hormone secretion

Tesamorelin stimulates physiological pulsatile release of endogenous growth hormone through direct activation of pituitary GHRH receptors.

Regolazione dell'IGF-1

Clinical studies consistently demonstrate increased circulating IGF-1 following Tesamorelin administration, making it an important research tool for GH-axis physiology.

Body composition

A major area of investigation has been the relationship between endogenous GH stimulation and changes in visceral adipose tissue and lean body mass.

Metabolic physiology

Researchers have also investigated hepatic fat metabolism, lipid regulation and broader metabolic adaptations associated with physiological GH release.

Why Tesamorelin is widely investigated in metabolic research

Among growth hormone secretagogues, Tesamorelin occupies a unique position because much of its research has focused on metabolic health rather than growth hormone deficiency alone.

Published studies have explored:

• visceral adipose tissue
• hepatic fat
• body composition
• metabolic syndrome
• IGF-1 physiology
• endocrine regulation
• HIV-associated lipodystrophy

This broad clinical evidence has made Tesamorelin one of the most important peptides for studying the interaction between the growth hormone axis and metabolic physiology.

Ricerca umana e preclinica

Tesamorelin has one of the strongest clinical evidence bases among all growth hormone secretagogues.

Multiple Phase III studies have investigated its effects on growth hormone secretion, visceral adipose tissue, lipid metabolism and hepatic fat. Unlike many research peptides, Tesamorelin has also received regulatory approval for one specific clinical indication, resulting in extensive long-term human safety and efficacy data.

How Tesamorelin differs from other GH secretagogues

Tesamorelin

• Analogo del GHRH
• Direct GHRH receptor activation
• Strong clinical evidence
• Extensive metabolic research

CJC-1295 (No DAC)

• Analogo del GHRH
• Longer research half-life
• Primarily experimental

Ipamorelin

• Agonista del recettore della grelina
• Secretagogo selettivo dell'ormone della crescita
• Minimal appetite effects

GHRP-2

• Potente agonista del recettore della grelina
• Robust GH pulses
• Fisiologia endocrina

GHRP-6

• Agonista del recettore della grelina
• Appetito e ricerca sull'ormone della crescita
• Fisiologia gastrointestinale
• Osservazioni di sicurezza pubblicate

Published clinical studies have generally reported Tesamorelin to be well tolerated. The most commonly reported adverse events included injection-site reactions, arthralgia, peripheral oedema and transient increases in IGF-1, with gastrointestinal effects occurring less frequently than with many modern metabolic peptides. Safety findings are derived from controlled clinical trials conducted primarily in patients with HIV-associated lipodystrophy.

Caratteristiche del prodotto

Applicazione: ricerca di laboratorio e analitica
Uso limitato: non per il consumo umano; non per uso medico, veterinario o cosmetico
Prodotto in stabilimenti conformi alle GMP secondo rigidi protocolli di controllo qualità.
Ogni lotto viene accuratamente testato in laboratorio dopo la produzione (puoi trovare il Certificato di Analisi sotto le immagini del prodotto).
Liofilizzato (liofilizzato) per la massima stabilità e una lunga durata di conservazione.
Sigillato in fiale sterili, pronto per la ricostituzione.
Purity: ≥ 99% (HPLC)
Aspetto: polvere liofilizzata bianca
Formula molecolare: C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight: 5135.78
CAS No: 218949-48-5

Archiviazioneflaconcini liofilizzati non aperti sono meglio conservati refrigerato a 2–8°C, che è il metodo di conservazione confermato dal nostro partner di produzione e adatto fino a 24 mesi. Si preferisce la refrigerazione perché minimizza inutili cicli di congelamento-scongelamento durante la manipolazione di routine. Se è necessaria una conservazione a termine sostanzialmente più lungo, i flaconcini liofilizzati non aperti possono anche essere conservati congelati. Una volta ricostituita, conservare sempre a 2-8°C e non congelare.

Ricostituzione e manipolazione

Tesamorelin is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with acqua batteriostatica prima dell'uso. Per aiutare a preservare l'integrità strutturale, aggiungere il solvente scelto lentamente contro la parete interna del flaconcino piuttosto che direttamente sulla polvere del peptide, ed evitare agitazioni vigorose. Il delicato movimento rotatorio è generalmente sufficiente una volta che il peptide si è completamente sciolto. La pratica standard di laboratorio include anche il far raggiungere ai flaconcini refrigerati la temperatura ambiente prima della ricostituzione per minimizzare la condensa all'interno del flaconcino.

Per altre indicazioni sulla scelta del solvente, sulla pianificazione della concentrazione e sullo stoccaggio, consultare il pieno Guida alla Ricostituzione dei Peptidi e Calcolatore di Ricostituzione.

Studi chiave pubblicati

• Falutz J, Allas S, Blot K, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine, 2007.

The pivotal Phase III study demonstrating reductions in visceral adipose tissue following Tesamorelin treatment while preserving lean body mass.

• Stanley TL, Feldpausch MN, Oh J, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation. JAMA, 2014.

A landmark study showing reductions in visceral and hepatic fat, expanding Tesamorelin research into metabolic liver physiology.

• Spooner LM, et al. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Drugs, 2012.

A comprehensive review covering pharmacology, mechanism of action and clinical development of Tesamorelin.

• Badran AS, et al. Body Composition, Hepatic Fat, Metabolic and Safety Outcomes of Tesamorelin: A Meta-analysis of Randomized Controlled Trials. Obesity Research & Clinical Practice, 2026.

A recent meta-analysis summarising clinical evidence for body composition, liver fat and metabolic outcomes across Tesamorelin trials.

Domande Frequenti

What is Tesamorelin?

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland through the GHRH receptor, promoting physiological pulsatile release of endogenous growth hormone. It is widely investigated in endocrine and metabolic research involving the GH/IGF-1 axis, body composition and visceral adipose tissue.

How does Tesamorelin differ from CJC-1295?

Both Tesamorelin and CJC-1295 are GHRH analogues that activate the same receptor pathway. Tesamorelin has an extensive clinical evidence base, including regulatory approval for HIV-associated lipodystrophy, whereas CJC-1295 remains primarily an experimental research peptide. Their receptor mechanism is similar, but their clinical development differs substantially.

How does Tesamorelin differ from Ipamorelin or GHRP peptides?

Tesamorelin stimulates growth hormone release through the GHRH receptor, while Ipamorelin, GHRP-2 and GHRP-6 activate the ghrelin receptor (GHSR-1a). These are complementary physiological pathways, which is why GHRH analogues and GHRP peptides are frequently investigated together in endocrine research.

Why is Tesamorelin widely investigated in metabolic research?

Beyond growth hormone physiology, Tesamorelin has been extensively studied for its effects on body composition, visceral adipose tissue, hepatic fat, lipid metabolism and IGF-1 regulation. This broad clinical evidence distinguishes it from many other growth hormone secretagogues.

What research areas commonly investigate Tesamorelin?

Published studies have investigated Tesamorelin in growth hormone secretion, IGF-1 regulation, pituitary physiology, body composition, visceral adipose tissue, hepatic fat, metabolic regulation and endocrine signalling.

Can Tesamorelin be combined with GHRP peptides in research?

Yes. Because Tesamorelin activates the GHRH receptor while GHRP peptides activate the ghrelin receptor, researchers frequently investigate these pathways together to study complementary mechanisms regulating pulsatile growth hormone secretion. Individual study designs vary, and findings should be interpreted within the context of the published research.

Questo prodotto è destinato all'uso umano?

No. Tesamorelin supplied by LIFE Peptide is provided strictly for laboratory and analytical research. It is not intended for human consumption, diagnosis, treatment or prevention of disease. Any discussion of published studies summarises the scientific literature relating to the Tesamorelin molecule rather than the intended use of this product.

Contesto di ricerca correlato

Tesamorelin belongs to the GHRH analogue and growth hormone signaling research class, which includes peptides investigated for endocrine regulation, GH-axis modulation, and pulsatile hormone release mechanisms.
Per una visione più ampia delle vie di segnalazione GH e dei meccanismi peptidici comparativi, consulta il nostro Guida alla ricerca sui peptidi dell'ormone della crescita.
I ricercatori che studiano l'interazione dell'asse GH potrebbero anche esaminare:

CJC-1295 (senza DAC)
Ipamorelin
GHRP-2
GHRP-6

Sfoglia tutti i composti in Categoria dei secretagoghi dell'ormone della crescita.
Ricercatori che studiano la regolazione endocrina possono anche esplorare composti in Ricerca metabolica, incluso GLP-1 e agonisti incretinici multipathway.

NOTA: Questo è solo a scopo didattico e non costituisce parere medico.

Disclaimer
Questo prodotto è venduto esclusivamente a scopo di ricerca. Non è destinato a diagnosticare, trattare, curare o prevenire alcuna malattia. L'acquirente si assume la piena responsabilità per la corretta manipolazione e utilizzo.